MSD Partners’s Oragenics OGEN Stock Holding History

MSD Partners’s Portfolio OGEN Stock Details OGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-24	Closed	-$49K	–	35
2018 Q3	$49K	Hold	24	–	–	﹤0.01%	36
2018 Q2	$59K	Buy	+24	New	+$63.1K	﹤0.01%	40
2018 Q1	–	Sell	-96	Closed	-$405K	–	36
2017 Q4	$405K	Hold	96	–	–	0.02%	21
2017 Q3	$724K	Hold	96	–	–	0.02%	31
2017 Q2	$638K	Hold	96	–	–	0.04%	34
2017 Q1	$757K	Hold	96	–	–	0.04%	33
2016 Q4	$932K	Hold	96	–	–	0.05%	30
2016 Q3	$794K	Hold	96	–	–	0.06%	29
2016 Q2	$880K	Hold	96	–	–	0.06%	48
2016 Q1	$1.55M	Hold	96	–	–	0.08%	54
2015 Q4	$2.59M	Hold	96	–	–	0.11%	44
2015 Q3	$2.83M	Hold	96	–	–	0.09%	53
2015 Q2	$2.36M	Hold	96	–	–	0.05%	60
2015 Q1	$1.76M	Hold	96	–	–	0.04%	67
2014 Q4	$1.53M	Hold	96	–	–	0.04%	62
2014 Q3	$2.16M	Hold	96	–	–	0.06%	54
2014 Q2	$3.36M	Hold	96	–	–	0.09%	54
2014 Q1	$4.95M	Hold	96	–	–	0.19%	50
2013 Q4	$4.85M	Buy	96 +22	+30%	+$1.15M	0.2%	53
2013 Q3	$3.98M	Hold	74	–	–	0.15%	51
2013 Q2	$4.11M	Buy	+74	New	+$4.19M	0.23%	40

Other funds holding OGEN

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

HWM

Holloway Wealth Management Gainesville, Florida $350M AUM 10.13% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

MSD Partners's OGEN Position: Q4 2018 in Review

MSD Partners sold out of Oragenics (OGEN) in Q4 2018, closing a stake of 24 shares — an estimated $49K sold.

MSD Partners first reported a position in OGEN in Q2 2013 and held it in 21 quarters. The position peaked at $4.95M in Q1 2014. 11 funds tracked by Wall St. Rank hold OGEN as of Q4 2018.

MSD Partners reported no remaining Oragenics position as of Q4 2018 after selling out during the quarter.
MSD Partners sold 24 Oragenics shares in Q4 2018, an estimated $49K.
MSD Partners first reported a position in Oragenics in Q2 2013 and held it in 21 quarters.
MSD Partners's Oragenics position peaked at $4.95M in Q1 2014.
11 funds tracked by Wall St. Rank held Oragenics as of Q4 2018.

Based on MSD Partners's 13F filing for Q4 2018, filed 14 Feb 2019.